Neurosessments: Developing a quick, objective motor test to prompt cognitivetesting in primary care

神经评估：开发快速、客观的运动测试以促进初级保健中的认知测试

• 批准号: 10759203
• 负责人: Jill Winquist Love
• 金额: $ 34.56万
• 依托单位: NEUROSESSMENTS LLC
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-09-30 至 2024-09-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10759203
• 关键词: Adopted; Adult; Affect; Age; Agreement; Alzheimer disease detection; Alzheimer' s Disease; Alzheimer' s disease brain; Alzheimer' s disease diagnosis; Alzheimer' s disease pathology; Alzheimer' s disease related dementia; American; Amyloid; Arizona; Behavioral; Black American; Black race; Brain; Brain Pathology; Caring; Cause of Death; Clinic; Clinical; Clinical assessments; Cognitive; Collection; Community Health; Copyright; Data; Decision Making; Dementia; Detection; Diagnosis; Diagnostic Reagent Kits; Diagnostic tests; Disease; Elderly; Evaluation; Family; Gifts; Goals; Individual; Intellectual Property; Judgment; Kidney Bean; Knowledge; Legal; Legal patent; Life; Link; Medical; Medical Staff; Memory; Motor; Movement; Neuropsychology; Nursing Students; Online Systems; Paper; Patient Education; Patient Self-Report; Patients; Phase; Physicians; Primary Care; Primary Care Physician; Probability; Process; Provider; Publishing; Racial Equity; Recommendation; Research; Research Assistant; Research Training; Rights; Sampling; Screening procedure; Self Care; Site; Small Business Innovation Research Grant; Specialist; Students; System; Technology; Testing; Time; United States; Universities; Upper Extremity; Visit; care providers; caucasian American; cerebral atrophy; clinical practice; cognitive testing; commercial application; commercialization; digital; early screening; empowerment; follow-up; functional decline; human old age (65+); improved; innovation; motor behavior; motor deficit; nursing administration; power analysis; pre-clinical; primary care provider; primary care setting; routine screening; screening; sex; technological innovation; tool development; usability

PROJECT SUMMARY/ABSTRACT Alzheimer’s disease (AD) is the leading cause of dementia in the United States, affecting one out of every nine older adults. However, Alzheimer’s disease and related dementias (AD/ADRD) can be difficult to diagnose, with physicians missing nearly half of all probable dementia cases. Rates of missed diagnosis are even higher among Black older adults. The majority of physicians do not regularly screen their patients with cognitive tests, due mostly to a lack of time during their face-to-face time with patients. Thus, there is a clear need for a quick, objective test that can be administered by medical staff prior to the physician’s time with the patient, which will prompt cognitive testing or a specialist referral for follow-up when there is concern for AD/ADRD. Since research has shown that motor regions in the brain are affected early in the progression of AD, the long-term goal of Neurosessments LLC is to develop a motor test that will help improve dementia detection in primary care that is appropriate for older adults from diverse backgrounds. Prior research by the Neurosessments LLC team has developed an experimental version of a motor test that can identify dementia, predict functional decline, and detect brain amyloid, regardless of the patient’s educational attainment, sex, or age. The overall objective of this Phase I SBIR is to adapt the original version of this motor test into a quick (<2 minutes) and easy to administer version called qBEANS (quick Behavioral Exam to Advance Neuropsychological Screening) for medical staff to use. The specific aims are to 1) determine the reliability and racial equity of a short version of the motor test and 2) develop a digital user interface for administering and scoring the motor test that is usable in a clinical setting. Achieving these aims will lead to a Phase II SBIR that deploys qBEANS within primary care offices and community health clinics to increase rates of cognitive testing and improve dementia detection. This proposal is innovative in its use of motor behavior to detect probable dementia in its early stages, and its development of tools for intended use in primary care. The commercialization plan is to sell single-use test kits to medical providers for use in primary care settings to annually screen adults ages 65 and older. Through routine screening, primary care providers will be able to identify individuals whose scores indicate possible dementia, informing providers of whether or not to perform additional cognitive testing or refer to specialists for possible diagnosis of AD/ADRD. The societal impact is that it will improve the rates of early dementia diagnosis, giving older adults and their families the gift of time to make decisions about treatment options, legal plans, personal care plans, and finances.

项目摘要/摘要 阿尔茨海默氏病（AD）是美国痴呆症的主要原因，每九个中的一个 老年人。但是，阿尔茨海默氏病和相关痴呆症（AD/ADRD）可能很难诊断 医师几乎缺少所有可能的痴呆病例。错过的诊断率甚至更高 黑人老年人。大多数医生不会定期对患者进行认知测试，应有 在与患者面对面的时间里，大多缺乏时间。那很明显需要快速， 在与患者的身体时间之前，医务人员可以进行客观测试，这将 当关注AD/ADRD时，请提示认知测试或专家转介进行随访。自研究以来 已经表明，大脑中的运动区域在AD的发展早期受到影响，这是长期目标 Neurosessments LLC是开发运动测试，该测试将有助于改善初级保健中的痴呆症检测 适合来自潜水员背景的老年人。 Neurosesses LLC团队的事先研究 开发了一个可以识别痴呆症，预测功能下降和的运动测试的实验版本 检测脑淀粉样蛋白，无论患者的教育程度，性别或年龄如何。总体目标 第一阶段SBIR是将此电动机测试的原始版本调整为快速（<2分钟），并且易于管理 称为QBEANS的版本（快速行为考试，以推进医务人员的神经心理学筛查） 使用。具体目的是1）确定电动机测试的简短版本的可靠性和种族平等和 2）开发一个数字用户界面，用于管理和评分临床环境中可用的运动测试。 实现这些目标将导致II期SBIR，该SBIR在初级保健办公室内部署QBEAN，并且 社区卫生诊所提高认知测试率并改善痴呆症检测。该提议是 在使用运动行为来检测有问题的痴呆症的创新性，并发展 用于初级保健的预期使用工具。商业化计划是将一次性测试套件出售给医疗 在年度屏幕筛查65岁及65岁以上的年度筛查的初级保健环境中使用的提供商。通过常规筛选， 初级保健提供者将能够识别出分数表明痴呆症的个人，并告知 提供者是是否执行其他认知测试或参考专家以获取可能的诊断 广告/adrd。社会影响是它将提高早期痴呆诊断的速度，从而为老年人提供 和他们的家人有时间的礼物，以决定治疗方案，法律计划，个人护理计划， 和财务。